Targeting the SerpinE1 axis could represent a novel strategy to disrupt the tumor-promoting microenvironment and reduce ctDNA levels in high-risk MM as already demonstrated in other cancer models [46]. This evidence concerns the gene SERPINE1 and Miyoshi myopathy.